The 2004 WHO classification of endocrine tumors defines pheochromocytoma as a tumor arising from catecholamine-producing chromaffin cells in the adrenal medulla -- an intra-adrenal paraganglioma.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Familial paraganglioma-pheochromocytoma syndrome is a hereditary condition indicated by the presence of tumors called paragangliomas and/or pheochromocytomas. Paranganglioma tumors arise from bundles ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.